The benefits of prophylactic defibrotide: Are the tides turning?
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31396 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Mahvish Q Rahim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology Oncology and Stem Cell Transplant, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Polydeoxyribonucleotides, Hepatic Veno-Occlusive Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Veno‐occlusive disease (VOD) is a life‐threatening endotheliopathy that can occur after stem cell transplant (SCT). Numerous risk factors contribute to the development of VOD during SCT, and the role of prophylactic defibrotide (DF) in mitigating these risks remains unclear.
Objective
We compare not only the incidence of VOD development, but also the severity of VOD and survival outcomes between patients who did and did not develop VOD and did or did not receive prophylactic DF. Study design In this single‐center retrospective study of 58 pediatric SCT patients from 2008 to 2022, we compare the demographics, risk profiles, and outcomes within three cohorts: Group 1: prophylactic DF and no VOD ( n = 5), Group 2: prophylactic DF and development of VOD ( n = 6), and Group 3: treatment DF for patients who developed VOD ( n = 47).
Results
Patients with VOD who did not receive prophylactic DF had higher severity classification of disease at onset (very severe 80.9% vs. 66.7%, p = .592) and at maximum severity (very severe 89.4% vs. 83.3%, p = .532), as opposed to mild, moderate, or severe categorization compared to those who did not receive prophylactic DF. Patients who developed VOD and did not receive prophylactic DF had a lower 1‐year survival probability compared to those who received prophylactic DF and still developed VOD (51.1% vs. 75% alive at 1 year, excluding the two subjects without adequate follow‐up time, p = .266).
Conclusion
Although, not statistically significant in our small retrospective study, there is potential overall survival and decreased VOD severity benefits of prophylactic DF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Hematology Oncology and Stem Cell Transplant, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA.
- Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Mahvish Q Rahim, Jodi Skiles
Zitieren
APA
Rahim, M. Q., Rahrig, A. L., Dinora, D., Harrison, J., Green, R., Carter, A., & Skiles, J. (2025). The benefits of prophylactic defibrotide: Are the tides turning?. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31396
Vancouver
Rahim MQ, Rahrig AL, Dinora D, Harrison J, Green R, Carter A, et al. The benefits of prophylactic defibrotide: Are the tides turning?. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31396
BibTeX
@article{Rahim2025,
author = {Rahim, Mahvish Q and Rahrig, April L and Dinora, Devin and Harrison, Jessica and Green, Ryanne and Carter, Allie and Skiles, Jodi},
title = {The benefits of prophylactic defibrotide: Are the tides turning?},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31396}
}
EUVIMED